160 related articles for article (PubMed ID: 31640596)
41. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.
De Mitri MS; Cassini R; Morsica G; Bagaglio S; Andreone P; Loggi E; Muratori P; Bernardi M
J Viral Hepat; 2006 Sep; 13(9):574-81. PubMed ID: 16907843
[TBL] [Abstract][Full Text] [Related]
42. Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.
Yoshikawa A; Terashita K; Morikawa K; Matsuda S; Yamamura T; Sarashina K; Nakano S; Kobayashi Y; Sogabe S; Takahashi K; Haba S; Oda H; Takahashi T; Miyagishima T; Sakamoto N
Clin J Gastroenterol; 2017 Jun; 10(3):270-273. PubMed ID: 28447325
[TBL] [Abstract][Full Text] [Related]
43. Emerging treatments for hepatitis C.
Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
[TBL] [Abstract][Full Text] [Related]
44. Virological Response to Conventional Interferon Therapy Combined with Ribavirin against Various HCV Genotypes in Khyber Pakhtunkhwa, Pakistan.
Ali S; Ahmad B; Ali I; Mahmood N; Anwar N; Saeedi I; Afridi JZ
Asian Pac J Cancer Prev; 2016; 17(5):2407-10. PubMed ID: 27268605
[TBL] [Abstract][Full Text] [Related]
45. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
Gill U; Aziz H; Gill ML
Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
[TBL] [Abstract][Full Text] [Related]
46. Compartmentalization of hepatitis C virus variants in patients with hepatocellular carcinoma.
Pérez PS; Di Lello FA; Mullen EG; Galdame OA; Livellara BI; Gadano AC; Campos RH; Flichman DM
Mol Carcinog; 2017 Feb; 56(2):371-380. PubMed ID: 27163636
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
[TBL] [Abstract][Full Text] [Related]
48. Consensus guidelines for the management of hepatitis C infection.
Consensus Guidelines Committee for the Management of Hepatitis C Infection
Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
[TBL] [Abstract][Full Text] [Related]
49. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
[TBL] [Abstract][Full Text] [Related]
50. [Hepatitis C virus: 25 years-old, the end?].
Pol S
Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
[TBL] [Abstract][Full Text] [Related]
51. Hepatitis C virus: How genetic variability affects pathobiology of disease.
Chayama K; Hayes CN
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():83-95. PubMed ID: 21199518
[TBL] [Abstract][Full Text] [Related]
52. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
Murphy MD; Rosen HR; Marousek GI; Chou S
Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
[TBL] [Abstract][Full Text] [Related]
53. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
[TBL] [Abstract][Full Text] [Related]
54. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Martin MT; Deming P
Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
[TBL] [Abstract][Full Text] [Related]
55. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy.
Babatin M; Schindel L; Burak KW
Can J Gastroenterol; 2005 Jun; 19(6):359-65. PubMed ID: 15997269
[TBL] [Abstract][Full Text] [Related]
56. Current status of hepatitis C virus infection in Korea.
Suh DJ; Jeong SH
Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
[TBL] [Abstract][Full Text] [Related]
57. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
58. [The impact of direct-acting antiviral therapy on the diagnosis of hepatitis-C virus-associated hepatocellular carcinoma].
Takahashi A; Shima T; Kinoshita N; Yano K; Ueno T; Nishiwaki M; Yamamoto Y; Oya H; Amano I; Matsumoto J; Mitsumoto Y; Tanaka I; Sakai K; Sawai N; Mizuno C; Mizuno M; Itoh Y; Okanoue T
Nihon Shokakibyo Gakkai Zasshi; 2018; 115(2):184-194. PubMed ID: 29459562
[TBL] [Abstract][Full Text] [Related]
59. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Med Virol; 2009 Mar; 81(3):459-66. PubMed ID: 19152412
[TBL] [Abstract][Full Text] [Related]
60. Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.
Mingorance L; Friesland M; Coto-Llerena M; Pérez-del-Pulgar S; Boix L; López-Oliva JM; Bruix J; Forns X; Gastaminza P
Antimicrob Agents Chemother; 2014 Jun; 58(6):3451-60. PubMed ID: 24709263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
